MA33747B1 - Anticorps monoclonaux diriges contre la progastrine et leurs utilisations - Google Patents
Anticorps monoclonaux diriges contre la progastrine et leurs utilisationsInfo
- Publication number
- MA33747B1 MA33747B1 MA34864A MA34864A MA33747B1 MA 33747 B1 MA33747 B1 MA 33747B1 MA 34864 A MA34864 A MA 34864A MA 34864 A MA34864 A MA 34864A MA 33747 B1 MA33747 B1 MA 33747B1
- Authority
- MA
- Morocco
- Prior art keywords
- monoclonal antibodies
- antibodies against
- methods
- progastrin
- gastrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des anticorps monoclonaux contre la progastrine, des fragments de ceux-ci, des compositions comprenant les anticorps monoclonaux contre la progastrine, et des procédés de fabrication et d'utilisation d'anticorps monoclonaux contre la progastrine ainsi que des compositions les contenant. La présente invention concerne des procédés de traitement du cancer colorectal avec des anticorps monoclonaux contre la progastrine et des compositions comprenant des anticorps monoclonaux contre la progastrine ou des fragments de ceux-ci. La présente invention concerne en outre des procédés comprenant la détection de la progastrine, y compris des procédés de diagnostic du cancer colorectal et des procédés de surveillance de l'efficacité d'une thérapie anticancéreuse chez des sujets souffrant du cancer colorectal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25262509P | 2009-10-16 | 2009-10-16 | |
PCT/EP2010/006329 WO2011045080A2 (fr) | 2009-10-16 | 2010-10-15 | Anticorps monoclonaux contre la progastrine et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33747B1 true MA33747B1 (fr) | 2012-11-01 |
Family
ID=43086711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34864A MA33747B1 (fr) | 2009-10-16 | 2012-05-11 | Anticorps monoclonaux diriges contre la progastrine et leurs utilisations |
Country Status (41)
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008076454A1 (fr) | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Compositions immunogènes comprenant de la progastrine, et utilisations de celles-ci |
US8136651B2 (en) * | 2007-12-14 | 2012-03-20 | The Procter & Gamble Company | Method and apparatus for orienting articles |
WO2011045080A2 (fr) * | 2009-10-16 | 2011-04-21 | Biorealites S.A.S. | Anticorps monoclonaux contre la progastrine et leurs utilisations |
US8900817B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
US9487582B2 (en) * | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
NZ602992A (en) * | 2010-03-24 | 2014-11-28 | Servier Lab | Prophylaxis of colorectal and gastrointestinal cancer |
EP2598531B1 (fr) * | 2010-07-26 | 2020-12-30 | Progastrine et Cancers S.à r.l. | Méthodes et compositions pour une thérapie contre le cancer du foie |
US8785603B2 (en) | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
EP2715364A1 (fr) | 2011-06-01 | 2014-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédé pour prédire le risque de développer une néoplasie du côlon |
EP3016683B1 (fr) | 2013-07-05 | 2020-06-24 | University of Washington through its Center for Commercialization | Anticorps monoclonal neutralisant la protéine mic soluble pour le traitement du cancer |
US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
EP3797793A1 (fr) * | 2014-04-18 | 2021-03-31 | The Research Foundation of the State University of New York at Buffalo | Anticorps humanisés anti-antigène tf |
WO2016066671A1 (fr) | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédé pour traiter des cancers résistants à l'aide d'inhibiteurs de la progastrine |
AU2016324021A1 (en) * | 2015-09-15 | 2018-04-12 | The Scripps Research Institute | Antibodies for generating anti-inflammatory macrophage and related uses |
TN2018000197A1 (en) * | 2015-12-31 | 2019-10-04 | Syncerus S A R L | Compositions and methods for assessing the risk of cancer occurrence |
WO2017114972A1 (fr) * | 2015-12-31 | 2017-07-06 | Progastrine Et Cancers S.À R.L. | Compositions et méthodes pour dépister et traiter le cancer de l'ovaire |
SG11201805141QA (en) * | 2015-12-31 | 2018-07-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating gastric cancer |
JP7071994B2 (ja) * | 2017-03-30 | 2022-05-19 | プロガストリン、エ、カンセル、エス、アー エル、エル | 前立腺がんを治療するための組成物および方法 |
ES2926532T3 (es) * | 2017-03-30 | 2022-10-26 | Progastrine Et Cancers S A R L | Composiciones y métodos para tratar el cáncer de pulmón |
JP7104153B2 (ja) * | 2017-12-05 | 2022-07-20 | プロガストリン、エ、カンセル、エス、アー エル、エル | 癌を治療するための抗プロガストリン抗体と免疫療法の併用療法 |
CA3085067A1 (fr) | 2017-12-08 | 2019-06-13 | Ecs-Biotracker Sarl | Progastrine radiomarquee dans le diagnostic du cancer |
WO2019145537A1 (fr) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combinaison de la détection de progastrine avec d'autres biomarqueurs du cancer dans le diagnostic du cancer |
EP3759492A1 (fr) * | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrine en tant que biomarqueur pour l'immunothérapie |
TWI793238B (zh) * | 2018-12-27 | 2023-02-21 | 偉喬生醫股份有限公司 | 體外檢測生物樣品之胃源性蛋白的方法及套組 |
CN112062846A (zh) * | 2020-04-27 | 2020-12-11 | 杭州博茵生物技术有限公司 | 一种g-17单克隆抗体及其应用 |
CN115785273B (zh) * | 2021-09-10 | 2023-10-31 | 东莞市朋志生物科技有限公司 | 一种抗胃蛋白酶原i的抗体及其应用 |
CN116143920A (zh) * | 2022-12-30 | 2023-05-23 | 南京岚煜生物科技有限公司 | 胃泌素17的单克隆抗体及其细胞株的制备方法和应用 |
CN118126177A (zh) * | 2023-11-22 | 2024-06-04 | 艾维可生物科技有限公司 | 抗成熟型胃泌素17的单克隆抗体及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
WO2006032980A1 (fr) * | 2004-09-22 | 2006-03-30 | Receptor Biologix, Inc. | Anticorps monoclonaux de progastrine |
CN101460196A (zh) * | 2006-05-22 | 2009-06-17 | 国立医学与健康研究所 | 在结肠癌治疗中的前胃泌素抑制剂 |
WO2008076454A1 (fr) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Compositions immunogènes comprenant de la progastrine, et utilisations de celles-ci |
EP2337795A2 (fr) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
WO2011045080A2 (fr) * | 2009-10-16 | 2011-04-21 | Biorealites S.A.S. | Anticorps monoclonaux contre la progastrine et leurs utilisations |
NZ602992A (en) * | 2010-03-24 | 2014-11-28 | Servier Lab | Prophylaxis of colorectal and gastrointestinal cancer |
-
2010
- 2010-10-15 WO PCT/EP2010/006329 patent/WO2011045080A2/fr active Application Filing
- 2010-10-15 SI SI201031788T patent/SI2488551T1/sl unknown
- 2010-10-15 AP AP2012006262A patent/AP2012006262A0/xx unknown
- 2010-10-15 AU AU2010306119A patent/AU2010306119A1/en not_active Abandoned
- 2010-10-15 KR KR1020127012677A patent/KR20120091221A/ko active Application Filing
- 2010-10-15 PL PL10768878T patent/PL2488551T3/pl unknown
- 2010-10-15 DK DK10768878.0T patent/DK2488551T3/en active
- 2010-10-15 CN CN201080057237.3A patent/CN102791735B/zh active Active
- 2010-10-15 EA EA201200597A patent/EA029271B1/ru not_active IP Right Cessation
- 2010-10-15 CN CN201410752851.1A patent/CN104628857A/zh active Pending
- 2010-10-15 NZ NZ599971A patent/NZ599971A/en unknown
- 2010-10-15 EP EP10768878.0A patent/EP2488551B1/fr active Active
- 2010-10-15 PL PL18185172.6T patent/PL3421493T3/pl unknown
- 2010-10-15 CA CA2777691A patent/CA2777691C/fr active Active
- 2010-10-15 US US12/906,041 patent/US9611320B2/en active Active
- 2010-10-15 NZ NZ701709A patent/NZ701709A/en unknown
- 2010-10-15 IN IN3348DEN2012 patent/IN2012DN03348A/en unknown
- 2010-10-15 KR KR1020157017085A patent/KR101640520B1/ko active IP Right Grant
- 2010-10-15 AR ARP100103784A patent/AR078659A1/es active IP Right Grant
- 2010-10-15 JP JP2012533531A patent/JP5985987B2/ja active Active
- 2010-10-15 LT LTEP10768878.0T patent/LT2488551T/lt unknown
- 2010-10-15 RS RS20181241A patent/RS57966B1/sr unknown
- 2010-10-15 TW TW099135321A patent/TWI537002B/zh active
- 2010-10-15 EP EP18185172.6A patent/EP3421493B1/fr active Active
- 2010-10-15 BR BR112012008818-1A patent/BR112012008818B1/pt active IP Right Grant
- 2010-10-15 ES ES18185172T patent/ES2973217T3/es active Active
- 2010-10-15 EA EA201791876A patent/EA201791876A1/ru unknown
- 2010-10-15 MX MX2012004400A patent/MX351635B/es active IP Right Grant
- 2010-10-15 SG SG10201704933PA patent/SG10201704933PA/en unknown
- 2010-10-15 PE PE2012000434A patent/PE20121649A1/es active IP Right Grant
- 2010-10-15 ES ES10768878.0T patent/ES2690943T3/es active Active
- 2010-10-15 GE GEAP201012707A patent/GEP201706604B/en unknown
- 2010-10-15 PT PT10768878T patent/PT2488551T/pt unknown
- 2010-10-15 UA UAA201205759A patent/UA106771C2/uk unknown
-
2012
- 2012-04-03 IL IL219019A patent/IL219019B/en active IP Right Grant
- 2012-04-04 TN TNP2012000159A patent/TN2012000159A1/en unknown
- 2012-04-11 CL CL2012000914A patent/CL2012000914A1/es unknown
- 2012-04-12 ZA ZA2012/02642A patent/ZA201202642B/en unknown
- 2012-04-13 EC ECSP12011796 patent/ECSP12011796A/es unknown
- 2012-04-13 CR CR20120184A patent/CR20120184A/es unknown
- 2012-04-13 NI NI201200054A patent/NI201200054A/es unknown
- 2012-04-13 HN HN2012000708A patent/HN2012000708A/es unknown
- 2012-04-16 GT GT201200114A patent/GT201200114A/es unknown
- 2012-04-16 CU CUP2012000060A patent/CU24196B1/es active IP Right Grant
- 2012-05-11 MA MA34864A patent/MA33747B1/fr unknown
-
2013
- 2013-05-20 HK HK13105899.6A patent/HK1178183A1/zh unknown
-
2015
- 2015-03-04 JP JP2015042849A patent/JP6272793B2/ja active Active
-
2017
- 2017-03-06 US US15/451,280 patent/US10385126B2/en active Active
- 2017-03-06 US US15/451,275 patent/US10377821B2/en active Active
- 2017-03-06 US US15/451,268 patent/US10385125B2/en active Active
- 2017-03-06 US US15/451,253 patent/US10385124B2/en active Active
- 2017-06-21 JP JP2017121372A patent/JP2017212992A/ja active Pending
- 2017-08-15 IL IL254004A patent/IL254004B2/en unknown
-
2018
- 2018-10-11 HR HRP20181645TT patent/HRP20181645T1/hr unknown
- 2018-10-22 CY CY181101081T patent/CY1120913T1/el unknown
-
2019
- 2019-06-28 US US16/456,328 patent/US11299542B2/en active Active
-
2022
- 2022-03-07 US US17/687,909 patent/US20220195035A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33747B1 (fr) | Anticorps monoclonaux diriges contre la progastrine et leurs utilisations | |
GB2463401B (en) | Characterizing prostate disorders by analysis of microvesicles | |
EP4357783A3 (fr) | Système et procédés hautement sensibles pour l'analyse de troponine | |
MA33256B1 (fr) | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation | |
WO2007035651A3 (fr) | Bio-essai de diagnostic du lupus erythemateux systemique | |
WO2010027903A8 (fr) | Diagnostic du cancer du poumon | |
WO2011015602A3 (fr) | Biomarqueurs du cancer du poumon | |
WO2011047033A3 (fr) | Biomarqueur d'identification de cellules tumorales de mélanome | |
EP1934377A4 (fr) | Procédés et compositions permettant d'identifier des biomarqueurs utiles au diagnostic et/ou au traitement d'états biologiques | |
WO2009090553A3 (fr) | Compositions et procédés de détection de peptides post-arrêts | |
DK2129391T3 (da) | Diagnostisk fremgangsmåde | |
MA30393B1 (fr) | Procede de traitement, de diagnostic ou de detection du cancer | |
MX2009011228A (es) | Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento. | |
WO2007084397A3 (fr) | Méthode de traitement de slpi par chymase | |
MX2009010751A (es) | Composiciones y metodos de deteccion. | |
EP2596121A4 (fr) | Procédé pour relier des résultats d'analyses diagnostiques rapides au point d'intervention à des procédés en laboratoire | |
WO2010031749A9 (fr) | Compositions et procédés pour détecter tlr3 | |
AU2010202926B2 (en) | Markers and methods relating to the assessment of Alzheimer's disease | |
WO2010044506A3 (fr) | Anticorps humain spécifique de tmprss4 | |
MX2019008005A (es) | Metodos y composiciones para diagnosticar preeclampsia. | |
GB2465907A (en) | VHZ for diagnosis and treatment of cancer | |
MA34291B1 (fr) | Compositions et méthodes de diagnostic et de traitement d'une tumeur | |
WO2007019276A3 (fr) | Detection quantitative de plomb dans de l'eau | |
NZ601643A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
MA30565B1 (fr) | Procede de diagnostic et traitement anticancereux |